The term “kite” refers to a device that’s attached to a boat.
In the case of pharmaceuticals such as Inovio Pharmaceuticals Inc, which manufactures anti-epileptic drugs for epilepsy, the company manufactures a Kite-C drug called Zephyr B. Inovion has developed an entire line of Kites, called Kite Pharma, that are attached to boats and have the ability to deliver powerful doses of the drug without the need for a drug-switching machine.
That technology has enabled the company to scale up its drug production capacity and deliver a new drug to patients quicker than it could with traditional drug-switch systems.
“Our current production line can produce as many as 1,000 tablets per day, and we are in the process of expanding that production capacity,” said Inovione CEO Dr. John M. Cawley.
“This technology will allow us to significantly expand the number of tablets available for our patients.”
The company is also developing a “kitty” that’s designed to fit on a boat and is intended to deliver the drugs to a patient’s feet.
This type of Kite is called a “ziploc” because it’s made of a single layer of plastic, which means the drugs are packaged in a ziploc bag, or the equivalent of a shopping bag.
In addition to a kite and its kite-like device, Inovior Pharmaceuticals is also working on a “tetraploid” or an alternative to a pill-switched Kite, which it calls a “triploid.”
This technology, which has been tested on mice, can produce a drug that has fewer side effects.
The company said the tetraploids will allow it to increase the dosage of drugs it makes from its existing production line.
“We believe we can take advantage of the current production pipeline and our ability to produce larger volumes of drugs, thereby increasing the likelihood that we will be able to offer the best possible product to our patients,” Cawleys said.
In its announcement last week, Inovo Pharmaceuticals said it expects to be producing the tetras for sale by the end of 2018.
The tetras will be available to consumers in about a year.
Inovo is working on other technologies to make drugs more efficient, including a new type of pill-switch system called “pulse flow” that will allow a KITE to dispense a dose of the medicine in less than 10 seconds.
The Kite and the drug will be sold through Inovius Therapeutics Inc. The drugs, which Inovios calls Kite Pharmacokinetic and Inovionskif, are expected to be available by 2021.
“Inovio is a leader in the medical device industry,” said Dr. Joseph D. Mathers, president of the American Society for Biochemistry and Molecular Biology.
“Its innovations have revolutionized the way we treat and manage serious diseases.
These new drugs will be a significant advance in our ability and ability to help patients with serious and complex diseases.”